08:50 AM EDT, 09/17/2025 (MT Newswires) -- GSK (GSK), Eli Lilly ( LLY ) , Johnson & Johnson ( JNJ ) , and AstraZeneca ( AZN ) are among the pharmaceutical firms that have pledged to invest more than $350 billion in the US amid the Trump administration's tariff threats, The Wall Street Journal reported Wednesday.

GSK said Wednesday it plans to invest $30 billion in research and development and supply chain infrastructure in the US over the next five years.

Eli Lilly ( LLY ) said Tuesday it plans to build a $5 billion manufacturing facility for active pharmaceutical ingredients and drug products in Virginia's Goochland County.

Johnson & Johnson ( JNJ ) said in August it would spend $2 billion over 10 years to expand manufacturing at a North Carolina site, while AstraZeneca ( AZN ) pledged in July to invest $50 billion on new manufacturing and research capacity in the US.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)